An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...

It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...